J&J Combines Ortho Biotech, Centocor
This article was originally published in The Pink Sheet Daily
At least 400 jobs lost to fallout from anemia-drug troubles.
You may also be interested in...
Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.
Second Phase III pivotal study backs fewer-dose benefit
Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.